Introduction: After years of limited success, progress of anti-cancer immuno-therapeutics has been considerable over the past decade. Key to this progress has been the application of new biological insights around the importance and nature of immune checkpoints that are able to reverse down-regulation of anti-tumor immunity.
Areas Covered: An overview of the preclinical and recent clinical trial data on key immuno-regulatory agents currently in development, including antibody targeting of cytotoxic T-lymphocyte antigen 4 (CTLA-4), programmed death receptor 1 (PD-1) on T-lymphocytes and its principal ligand (PD-L1) on tumor cells as well as immune agonists (e.g., anti-CD40).
Expert Opinion: Durable long-term responses in some patients with advanced melanoma, initially with ipilimumab (anti-CTLA-4) and more recently antibodies targeting either PD-1 or PD-L1 in patients with melanoma and renal cancer, non-small-cell lung, bladder and head and neck cancers with less toxicity, have provided real optimism that immunotherapeutic approaches can improve outcomes in a wide range of cancer. The manageable tolerability of PD-1-pathway blockers and their unique mechanism of action are encouraging combination approaches. Current efforts focus on registration trials of single agents plus combinations in many different tumor types and treatment settings and identifying and developing predictive biomarkers of immunological response.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1517/14712598.2015.1036737 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
The impact of inhalation versus total intravenous anesthesia on the immune status in patients undergoing breast cancer surgery: a double-blind randomized clinical trial (TeMP).
Front Oncol
July 2024
Department of Clinical Trials and intelligent IT, Federal Research and Clinical Centre of Intensive Care Medicine and Rehabilitology, Moscow, Russia.
Background: Breast cancer (BC) mortality primarily stems from metastases rather than the primary tumor itself. Perioperative stress, encompassing both surgical and anesthetic factors, profoundly impacts the immune system, leading to alterations in neuroendocrine pathways and immune functions, potentially facilitating tumor progression and metastasis. Understanding the immunomodulatory effects of different anesthesia techniques is crucial for optimizing perioperative care in patients with BC.
View Article and Find Full Text PDFEpacadostat plus pembrolizumab versus placebo plus pembrolizumab as first-line treatment for metastatic non-small cell lung cancer with high levels of programmed death-ligand 1: a randomized, double-blind phase 2 study.
BMC Cancer
July 2024
Department of Oncology, Division of Medical Oncology, Cross Cancer Institute, Edmonton, Canada.
Article Synopsis
- - The study investigated the combination of pembrolizumab and epacadostat as a treatment for advanced non-small cell lung cancer (NSCLC) patients with high PD-L1 expression, aiming to see if it improved outcomes compared to pembrolizumab alone.
- - A total of 154 patients were involved, showing similar overall response rates (32.5% for combination vs. 39.0% for control) and comparable progression-free survival (around 6.7 months for combination vs. 6.2 months for control).
- - Notably, while the combination treatment led to a decrease in circulating kynurenine levels, common serious side effects included pneumonia and anemia; most patients did not normalize kynurenine
Late-onset and long-lasting neutropenias in the young: A new entity anticipating immune-dysregulation disorders.
Am J Hematol
April 2024
Haematology Unit-IRCCS Istituto Giannina Gaslini, Genova, Italy.
This study identifies a new chronic form of immune neutropenia in the young with or without detectable indirect anti-neutrophil antibodies, characterized by mild/moderate neutropenia low risk of severe infection (14%), tendency to develop autoimmune phenomena over the course of the disease (cumulative incidence of 58.6% after 20 years of disease duration), leukopenia, progressive reduction of absolute lymphocyte count and a T- and B-cell profile similar to autoimmune disorders like Sjogren syndrome, rheumatoid arthritis, and systemic lupus erythematosus (increased HLADR+ and CD3 + TCRγδ cells, reduced T regulatory cells, increased double-negative B and a tendency to reduced B memory cells). In a minority of patients, P/LP variants related to primary immuno-regulatory disorders were found.
View Article and Find Full Text PDFUnveiling CD59-Antibody Interactions to Design Paratope-Mimicking Peptides for Complement Modulation.
Int J Mol Sci
May 2023
Institute of Biostructures and Bioimaging (IBB), National Research Council (CNR), I-80131 Napoli, Italy.
CD59 is an abundant immuno-regulatory human protein that protects cells from damage by inhibiting the complement system. CD59 inhibits the assembly of the Membrane Attack Complex (MAC), the bactericidal pore-forming toxin of the innate immune system. In addition, several pathogenic viruses, including HIV-1, escape complement-mediated virolysis by incorporating this complement inhibitor in their own viral envelope.
View Article and Find Full Text PDFModulation of the Gal-9/TIM-3 Immune Checkpoint with α-Lactose. Does Anomery of Lactose Matter?
Cancers (Basel)
December 2021
University of Lille, CNRS, Inserm, CHU Lille, UMR9020-UMR1277-Canther-Cancer Heterogeneity, Plasticity and Resistance to Therapies, 59000 Lille, France.
The disaccharide lactose is an excipient commonly used in pharmaceutical products. The two anomers, α- and β-lactose (α-L/β-L), differ by the orientation of the C-1 hydroxyl group on the glucose unit. In aqueous solution, a mutarotation process leads to an equilibrium of about 40% α-L and 60% β-L at room temperature.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!